A critical role for natural killer cells in dendritic cell-based anticancer immunotherapy

Abstract

Multipronged immunotherapies that activate both T cells and natural killer (NK) cells may result in more robust and durable anticancer responses. The successful outcome of dendritic cell (DC)-based vaccination therapy involves a hitherto unrecognized role for NK cells. Combinatorial regimens that enhance the contribution of NK cells to the anticancer immune response may therefore improve clinical outcomes.

Keywords::

• cancer
• immunotherapy
• dendritic cell
• melanoma
• natural killer cell
• Models of anticancer vaccination
• Dendritic cell-based vaccines